LLNEXT batch-2 6GB Illumina
Awarded
The competition has ended and a winner has been selected.
- Deadline
- Apr 8,Expired
- Award
Brief
Universitair Medisch Centrum Groningen (UMCG) / Poliklinische Apotheek UMCG heeft een overeenkomst gesloten met Biomarker Technologies (BMK) GmbH voor de levering van onderzoeks laboratoriumdiensten, specifiek de tweede batch van het LLNEXT-project, gericht op de rol van maternale en vroege levensmicrobioom in de gezondheid van zuigelingen. De diensten omvatten DNA-isolatie van fecale monsters, waarbij monsters van jonge zuigelingen lage DNA-concentraties hebben. De overeenkomst heeft een waarde van 1 euro. Er waren 4 inschrijvingen.
Forsknings- og analyselaboratorier
Result
- Biomarker Technologies (BMK) GmbHWinner
- 4Number of tenders received
- €1Contract value
Previous winners
Who are you up against?
The suppliers who have won similar contracts at Universitair Medisch Centrum Groningen (UMCG) / Poliklinische Apotheek UMCG
Will you bid?
The agent sets up the bid and writes the first draft. Free for 14 days.
Award Criteria
Description
The Contracting Authority intends to award the Contract to the one Tenderer with the lowest price. The Contracting Authority will weigh the price criteria to reach a final assessment.
Source
No source found in the documents. Check the weight against the tender documents.
From the notice
Second batch of the LLNEXT project. The aim is to look at the role of maternal and early life microbiome in infant health. DNA isolated from fecal samples, dissolved in ATE buffer. Samples from early timepoints (babies of 2 weeks) have low DNA concentrations (4-5ng/ul)
Contact
Auke Oosta.h.oost@umcg.nl- Result · Dynamic purchasing systemType
- 73111000Main codeResearch laboratory services